PRESS RELEASE, January 20th 2026

TRiCares Enters into €20 million Loan Agreement with the European Investment Bank

Paris, France and Munich, Germany, 20 January 2026 – TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today announces it has secured up to €20 million in non-dilutive financing from the European Investment Bank (EIB), the long-term lending institution of the European Union.

This facility has been granted to provide flexible financing support for TRiCares’ research, development and innovation activities, including advancing clinical studies of Topaz, its Transfemoral Tricuspid Heart Valve Replacement (TTVR) System. The ongoing European pivotal study (NCT06581471) is taking place in sites across Belgium, Denmark, France, Germany and Spain, with Switzerland to follow. A total of 80 patients will be enrolled. The TRICURE US Early Feasibility Study (NCT06506942) is also making solid progress. To date, implantations have taken place at major structural heart institutions across the US, with a total of 15 patients to be enrolled across 8 sites.

Ahmed Elmouelhi, President & CEO of TRiCares, said: “We are pleased to have secured this loan agreement with the EIB, which is a clear validation of our approach and will be a valuable resource to support our clinical trials in the U.S. and Europe. We believe that Topaz has the potential to transform outcomes for tricuspid patients, and we look forward to providing further updates from our ongoing studies and plans to begin our IDE pivotal trial.”

Details of the project are published on the EIB website here.